Annovis Bio (ANVS) Projected to Post Earnings on Friday

Annovis Bio (NYSE:ANVS) is anticipated to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.

Annovis Bio (NYSE:ANVS) last announced its earnings results on Friday, March 21st. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). During the same period last year, the business posted ($0.43) EPS. On average, analysts expect Annovis Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Annovis Bio Stock Down 0.5 %

Shares of NYSE:ANVS opened at $1.84 on Friday. The firm’s 50-day simple moving average is $2.76 and its 200-day simple moving average is $5.59. Annovis Bio has a fifty-two week low of $1.53 and a fifty-two week high of $20.00. The company has a market cap of $26.19 million, a price-to-earnings ratio of -0.41 and a beta of 1.65.

Analysts Set New Price Targets

Separately, D. Boral Capital restated a “hold” rating on shares of Annovis Bio in a research report on Monday, February 10th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $37.00.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.